Adjuvant therapy approaches to breast cancer: Should taxanes be incorporated?

Current Oncology Reports

Volumn 5, Issue 1, 2003, Pages 66-71

  Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; PREDNISOLONE; TAMOXIFEN; TAXANE DERIVATIVE; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ASTHENIA; AXILLARY LYMPH NODE; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER RESEARCH; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHRONOTHERAPY; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG FATALITY; EARLY CANCER; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LYMPH NODE METASTASIS; REVIEW; SEPSIS; STATISTICAL SIGNIFICANCE;

EID: 2542431903     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-003-0089-4     Document Type: Review

References (22)

1. Chan S, Friedrichs K, Noel D, et al.: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999, 17:2341-2354.
2. Nabholtz J-M, Gelmon K, Bontenbal M, et al.: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996, 14:1858-1867.
3. Nabholtz JM, Senn HJ, Bezwoda WR, et al.: Prospective randomized trial of docetaxel versus mitoxantrone plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 1999, 17:1413-1424.
4. Peretz T, Sulkes A, Chollet P, et al.: A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC). Eur J Cancer 1995, 31(Suppl 5):S75.
5. Seidman AD, Tiersten A, Hudis C, et al.: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995, 13:2575-2581.
6. Sjöström J, Blomqvist C, Mouridsen H, et al.: Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomized phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999, 35:1194-1201.
7. Nabholtz J-M, Pienkowski T, Mackey J, et al.: Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study [abstract]. Proc ASCO 2002, 21:36a.
8. Mackey JR, Cantin J, Chang J, et al.: Role of hematopoietic growth factors in the prevention of neutropenic complications for breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide (TAC): results of a randomized double-blind phase III trial - BCIRG 004 [abstract]. Proc ASCO 2001, 20:10a.
9. Henderson IC: Adjuvant chemotherapy: taxanes - the 'pro' position. Presentation at the National Institutes of Health Consensus Conference: Adjuvant Therapy for Breast Cancer. Bethesda, MD, November 1-3, 2000. http://consensus.nighgov/cons/114/114_abstract.pdf
10. Henderson IC, Berry D, Demetri G, et al.: Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer [abstract]. Proc ASCO 1998, 17:101a.
11. Mamounas EP: Evaluating the use of paclitaxel following doxorubicin/cyclophosphamide in patients with breast cancer and positive axillary nodes. Presentation at the National Institutes of Health Consensus Conference: Adjuvant Therapy for Breast Cancer. Bethesda, MD, November 1-3, 2000. http://consensus.nighgov/cons/114/114_abstract.pdf
12. Taxol [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2000.
13. Norton L: Of mice, telomerase, and PTEN. Presentation at the Presidential Symposium: Multidisciplinary Approach to Treating Breast Cancer at the at the 38th Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, May 18-21, 2002 http://www.asco.org
14. National Surgical Adjuvant Breast and Bowel Project: The effect on primary tumor response of adding sequential Taxotere to Adriamycin and cyclophosphamide: preliminary results from NSABP Protocol B-27 [abstract]. Breast Cancer Res Treat 2001, 69:210.
15. Buzdar AU, Singletary SE, Theriault RL, et al.: Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999, 17:3412-3417.
16. Buzdar AU, Singletary SE, Valero, V, et al.: Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 2002, 8:1073-1079.
17. Hutcheon AW, Heys SD, Miller ID, et al., for the Aberdeen Breast Group: Improvements in survival in patients receiving primary chemotherapy with docetaxel for breast cancer: a randomised controlled trial [abstract]. Breast Cancer Res Treat 2001, 69:298.
18. Smith IC, Heys SD, Hutcheon AW, et al.: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002, 20:1456-1466.
19. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998, 352:930-942.
20. Peto R: EBCTCG: Updated results from September 2000 worldwide overview [abstract]. Eur J Cancer 2000, 36(Suppl 5): S47.
21. National Surgical Adjuvant Breast and Bowel Project: NSABP Clinical Trials Overview: Protocol B-30. http://www.nsabp.pitt.edu/B-30.htm
22. Swain SM: Phase III randomized study of adjuvant doxorubicin and cyclophosphamide followed by docetaxel versus doxorubicin and docetaxel versus doxorubicin, docetaxel, and cyclophosphamide in women with breast cancer and positive axillary lymph nodes. Protocol CTSU, NSABP-B-30. http://www.cancer.gov